← Back to Search

Other

High-Risk or Relapsed Hodgkin Lymphoma for Lymphoma

Phase 2
Waitlist Available
Led By Juliet Barker, MBBS
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 8 years
Awards & highlights

Study Summary

This trial is testing how well giving chemotherapy before a donor stem cell transplant helps patients with relapsed or high-risk Hodgkin lymphoma.

Eligible Conditions
  • Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 8 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 8 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression-free Survival at 1 Year
Secondary outcome measures
Disease Relapse or Progression as Measured by CT Scan or PET
Overall Survival

Trial Design

1Treatment groups
Experimental Treatment
Group I: High-Risk or Relapsed Hodgkin LymphomaExperimental Treatment19 Interventions
This is a phase 2 intention-to-treat study of salvage chemotherapy followed by allogeneic HSC transplant for the treatment of primary refractory or relapsed HL. Patients who 1) do not progress on salvage chemotherapy, and 2) have both suitable HSC donors and 3) a satisfactory pre-allograft work-up will proceed to allograft. Patients who fail any of these 3 criteria will be off-study and considered treatment failures for the purposes of the intention-to-treat study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
mechlorethamine hydrochloride
2007
Completed Phase 2
~30
procarbazine hydrochloride
1994
Completed Phase 3
~4560
vinorelbine tartrate
1998
Completed Phase 3
~1940
allogeneic bone marrow transplantation
2005
Completed Phase 3
~5000
nonmyeloablative allogeneic hematopoietic stem cell transplantation
1999
Completed Phase 3
~640
methotrexate
1997
Completed Phase 3
~9960
allogeneic hematopoietic stem cell transplantation
2005
Completed Phase 3
~890
peripheral blood stem cell transplantation
1997
Completed Phase 3
~4330
total-body irradiation
2000
Completed Phase 3
~1250
prednisone
1999
Completed Phase 3
~10920
mycophenolate mofetil
2000
Completed Phase 3
~1730
umbilical cord blood transplantation
2008
Completed Phase 3
~1120
vincristine sulfate
1994
Completed Phase 3
~11270
cyclosporine
2000
Completed Phase 3
~1290
gemcitabine hydrochloride
1997
Completed Phase 2
~990
ifosfamide
1999
Completed Phase 3
~2230
cyclophosphamide
1994
Completed Phase 3
~8140
melphalan
1994
Completed Phase 3
~3530
fludarabine phosphate
2000
Completed Phase 3
~2660

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,651 Previous Clinical Trials
40,932,905 Total Patients Enrolled
1,380 Trials studying Lymphoma
382,340 Patients Enrolled for Lymphoma
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,933 Previous Clinical Trials
585,354 Total Patients Enrolled
154 Trials studying Lymphoma
8,676 Patients Enrolled for Lymphoma
Juliet Barker, MBBSPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
6 Previous Clinical Trials
258 Total Patients Enrolled
3 Trials studying Lymphoma
164 Patients Enrolled for Lymphoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
2007. "Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00574496.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top